Indeed, pharmacological inhibition of either NAMPT or the mitochondrial Electron Transport Chain (ETC), administered in combination with BRAFi, restores the responsiveness of RICTOR-deficient-cells to the drug, suggesting that the NAMPT/ETC axis likely represents a specific therapeutic vulnerability of mTORC2-deficient melanomas. This evidence concerns the gene NAMPT and melanoma.